4-aminopyridine has been researched along with Carcinoma, Non-Small Cell Lung in 2 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Mouse oral bioavailability was complete (100%) with extensive tumor exposure." | 1.43 | The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma. ( Aherne, GW; Box, G; Boxall, KJ; Collins, I; De Haven Brandon, AK; Eccles, SA; Eve, PD; Garrett, MD; Hayes, A; Henley, AT; Hunter, JE; Lainchbury, M; Matthews, TP; McHardy, T; Osborne, J; Perkins, ND; Raynaud, FI; Reader, JC; Swales, K; Tall, M; Valenti, MR; Walton, MI, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tjin Tham Sjin, R | 1 |
| Lee, K | 1 |
| Walter, AO | 1 |
| Dubrovskiy, A | 1 |
| Sheets, M | 1 |
| Martin, TS | 1 |
| Labenski, MT | 1 |
| Zhu, Z | 1 |
| Tester, R | 1 |
| Karp, R | 1 |
| Medikonda, A | 1 |
| Chaturvedi, P | 1 |
| Ren, Y | 1 |
| Haringsma, H | 1 |
| Etter, J | 1 |
| Raponi, M | 1 |
| Simmons, AD | 1 |
| Harding, TC | 1 |
| Niu, D | 1 |
| Nacht, M | 1 |
| Westlin, WF | 1 |
| Petter, RC | 1 |
| Allen, A | 1 |
| Singh, J | 1 |
| Walton, MI | 1 |
| Eve, PD | 1 |
| Hayes, A | 1 |
| Henley, AT | 1 |
| Valenti, MR | 1 |
| De Haven Brandon, AK | 1 |
| Box, G | 1 |
| Boxall, KJ | 1 |
| Tall, M | 1 |
| Swales, K | 1 |
| Matthews, TP | 1 |
| McHardy, T | 1 |
| Lainchbury, M | 1 |
| Osborne, J | 1 |
| Hunter, JE | 1 |
| Perkins, ND | 1 |
| Aherne, GW | 1 |
| Reader, JC | 1 |
| Raynaud, FI | 1 |
| Eccles, SA | 1 |
| Collins, I | 1 |
| Garrett, MD | 1 |
2 other studies available for 4-aminopyridine and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing.
Topics: 4-Aminopyridine; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Clin | 2014 |
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.
Topics: 4-Aminopyridine; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; C | 2016 |